VAL Share PerformanceMore
|52 week high||7.7100 20/12/17|
|52 week low||0.9000 15/11/17|
|52 week change||0.4500 (17.65%)|
|4 week volume||140,266,875 28/03/18|
Media for (VAL)
Latest News« previous» nextMore
20/04/2018 - 10:43 RNS
Hardman & Co Research Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year 20-Apr-2018 / 10:43 GMT/BST Hardman & Co Research: 2017: a pivotal year ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets are in clinical trials: VAL201 (Phase I/...
19/04/2018 - 11:58 StockMarketWire
The FTSE 100 enjoyed modest gains amid a raft of mostly positive corporate news, trading 0.1% higher at 7,327 around mid...
19/04/2018 - 07:00 RNS
RNS Number: 3747L ValiRx PLC 19 April 2018 ValiRx Plc ("ValiRx" or the "Company") GENEICE & VAL101 UPDATE "Positive results from VAL101 shown to be effective in inducing apoptosis (programmed cell death) in cancer cell models" London, UK ., 19 April 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce posit...
12/04/2018 - 07:00 RNS
RNS Number: 6465K ValiRx PLC 12 April 2018 ValiRx Plc ("ValiRx" or the "Company") Posting of Annual Report and Accounts & Notice of Annual General Meeting London, UK, 12 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medic...
10/04/2018 - 07:46 StockMarketWire
Cancer therapy developer ValiRx said annual losses narrowed following a reduction in R&D costs and administrative expe...
10/04/2018 - 07:00 RNS
RNS Number: 3252K ValiRx PLC 10 April 2018 VALIRX PLC ("ValiRx", "the Company" or "the Group") FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 London, UK, 10 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision ...
10/04/2018 - 00:00 BRR Media
20/03/2018 - 09:12 StockMarketWire
ValiRx said it had been granted a patent in the US for its lead therapeutic compound for treating cancer, which was in cli...
|Dividend yield||0 %|
Latest discussion posts More
“thanks for sharing your views and supporting arguement. Agreed...we are woefully undervalued. 3 weeks is a long time on aim. As we are so heavily reliant on small pi's, it ...”▼
“Can 't get on any board on LSE but can still get on to other sites..is it ...”▼
“Dear all I guess today?s huge trading volume would have finally seen shot of YA (assuming they had any shares left to sell, as once they went below the 3% radar we would never ...”▼
Codes & Symbols
|Symbols||VAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL|